NDAORALTABLET, FOR SUSPENSION
Lifecycle
Pre-Launch
Clinical Trials
3
Data completeness
3/8 — Basic
ABACAVIR AND LAMIVUDINE (abacavir; lamivudine) by Cipla is hiv-1 [see ] . Approved for human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of hiv-1 infection.
Drug data last refreshed 2w ago
Mechanism of Action
HIV-1 [see ] .
Clinical Trials (3)
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
Started Mar 2020
25 enrolled
HIV-1-infection
Abacavir and Lamivudine PK in Children
Started Jul 2012
30 enrolled
HIV
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
Started Jul 2004
900 enrolled
HIV Infection
Worked on ABACAVIR AND LAMIVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.